Rhei To Market ADHD Nutraceutical Attental In China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Rhei Pharmaceuticals and MethaPharma have inked a deal under which Rhei gains exclusive rights to market and distribute MethaPharma's proprietary nutraceutical product Attental for treating attention-deficit hyperactivity disorder throughout Asia, the two companies announced Feb. 19